Medscape Medical News > Conference News > EASD 2024 Nancy A. Melville September 19, 2024 MADRID — The benefits of semaglutide treatment in reducing kidney disease, cardiovascular, and mortality risks in people with type 2 diabetes and chronic kidney disease (CKD) are observed regardless of whether patients are also being treated with mineralocorticoid receptor antagonists...
Tag: <span>Semaglutide</span>
Post
Signal of Suicidality With GLP-1 RA Semaglutide, but Experts Urge Caution
Medscape Medical News Megan Brooks August 20, 2024 A new analysis has detected a signal of suicidal ideation associated with the glucagon-like peptide 1 receptor agonist (GLP-1 RA) semaglutide, especially among individuals concurrently using antidepressants or benzodiazepines. However, the investigators and outside experts urge caution in drawing any firm conclusions based on the study’s observations....
Post
Semaglutide’s cardiovascular benefits are maintained in people with impaired kidney function, research finds
September 11, 2024 by Diabetologia Credit: Pixabay/CC0 Public DomainThe anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with overweight or obesity who don’t have diabetes, whether or not they also have impaired kidney function, according to new research to be...
Post
Analysis finds no increased risk of mental health issues among those using semaglutide for weight loss
September 3, 2024 by Perelman School of Medicine at the University of Pennsylvania Credit: Unsplash/CC0 Public DomainTaking the weight loss medication semaglutide did not increase the risk of depressive symptoms, suicidal thoughts, or suicidal behavior in persons without known major mental health disorders, according to a new study led by researchers from the Perelman School...
Post
Is Semaglutide the ‘New Statin’? Not So Fast
Medscape Diabetes & EndocrinologyCOMMENTARY Kevin Fernando, MBChB, MSc Diabetes, BSc DISCLOSURES | June 03, 2024 There has been much hyperbole since the presentation of results from the SELECT cardiovascular outcomes trial (CVOT) at this year’s European Congress on Obesity, which led many to herald semaglutide as the “new statin.” In the SELECT CVOT, participants with...
Post
Semaglutide products being sold online without prescriptions
August 3, 2024 by Elana Gotkine Semaglutide products are being sold online, with products likely unregistered or unlicensed, according to a research letter published online Aug. 2 in JAMA Network Open. Amir Reza Ashraf, Pharm.D., from the University of Pécs in Hungary, and colleagues conducted a risk assessment of semaglutide online sourcing. Websites advertising semaglutide...
Post
Does Semaglutide Make You Blind? Here’s How the Popular Weight-Loss Drug Can Affect Your Eyes
Written by Sophie Vergnaud, MD | Reviewed by Alyssa Billingsley, PharmDUpdated on July 8, 2024 Key takeaways: New research has shown a link between taking semaglutide (Ozempic, Wegovy) and a rare kind of eye stroke called non-arteritic anterior ischemic optic neuropathy (NAION) — especially in the first year of taking the medication. Semaglutide has also...
Post
Study shows sedative exams like endoscopy may require prolonged fasting for semaglutide users
JULY 3, 2024 by D’Or Institute for Research and Education Credit: CC0 Public DomainA study published in the Journal of Clinical Anesthesia investigated the relationship between semaglutide use and residual gastric content in patients undergoing upper gastrointestinal endoscopy (EGD). Conducted by researchers at the D’Or Institute for Research and Education (IDOR), the retrospective study analyzed...
Post
Study finds semaglutide associated with reduction in incidence and recurrence of alcohol-use disorder
JUNE 3, 2024 by Case Western Reserve University Credit: Pixabay/CC0 Public DomainA new study by researchers at the Case Western Reserve University School of Medicine reveals that the popular diabetes and weight-loss drugs Wegovy and Ozempic are linked to reduced incidence and recurrence of alcohol abuse or dependence. The team’s findings, recently published in the...
Post
AAO: Diabetic retinopathy usually no worse with semaglutide in T2D
by Elana Gotkine For patients with type 2 diabetes mellitus, most eyes have no worsening of diabetic retinopathy (DR) after initiation of semaglutide, according to a study presented at the annual meeting of the American Academy of Ophthalmology, held from Nov. 3 to 6 in San Francisco. Zeeshan Haq, M.D., from Retina Consultants of Minnesota...